{"title":"Pembrolizumab联合化疗治疗晚期鳞状细胞肺癌患者-临床试验和现实世界数据","authors":"Magdalena Knetki-Wróblewska, Dariusz M. Kowalski","doi":"10.5603/ocp.2023.0047","DOIUrl":null,"url":null,"abstract":"Advanced squamous-cell lung carcinoma remains a disease with an unfavorable prognosis. Until recently, chemotherapy was used in systemic treatment, and its effectiveness was limited. Implementation of immune check-point inhibitors allowed for an improvement in treatment results. The KEYNOTE-407 study included patients with squamous-cell lung cancer who received 4 immunochemotherapy cycles followed by maintenance treatment with pembrolizumab. Median overall survival of 17.2 months versus 11.6 months for chemotherapy was obtained (risk of death reduction by 29%) while the percentage of patients remaining in follow-up was 18%. Analysis of patients with good performance status treated in clinical practice confirms the results from the registration study and emphasizes the importance of taking into consideration clinical factors while qualifying patients for treatment.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"10 1","pages":"0"},"PeriodicalIF":0.3000,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pembrolizumab in combination with chemotherapy in patients with advanced squamous cell lung cancer — clinical trials and real-world data\",\"authors\":\"Magdalena Knetki-Wróblewska, Dariusz M. Kowalski\",\"doi\":\"10.5603/ocp.2023.0047\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Advanced squamous-cell lung carcinoma remains a disease with an unfavorable prognosis. Until recently, chemotherapy was used in systemic treatment, and its effectiveness was limited. Implementation of immune check-point inhibitors allowed for an improvement in treatment results. The KEYNOTE-407 study included patients with squamous-cell lung cancer who received 4 immunochemotherapy cycles followed by maintenance treatment with pembrolizumab. Median overall survival of 17.2 months versus 11.6 months for chemotherapy was obtained (risk of death reduction by 29%) while the percentage of patients remaining in follow-up was 18%. Analysis of patients with good performance status treated in clinical practice confirms the results from the registration study and emphasizes the importance of taking into consideration clinical factors while qualifying patients for treatment.\",\"PeriodicalId\":42942,\"journal\":{\"name\":\"Oncology in Clinical Practice\",\"volume\":\"10 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2023-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology in Clinical Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/ocp.2023.0047\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology in Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ocp.2023.0047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Pembrolizumab in combination with chemotherapy in patients with advanced squamous cell lung cancer — clinical trials and real-world data
Advanced squamous-cell lung carcinoma remains a disease with an unfavorable prognosis. Until recently, chemotherapy was used in systemic treatment, and its effectiveness was limited. Implementation of immune check-point inhibitors allowed for an improvement in treatment results. The KEYNOTE-407 study included patients with squamous-cell lung cancer who received 4 immunochemotherapy cycles followed by maintenance treatment with pembrolizumab. Median overall survival of 17.2 months versus 11.6 months for chemotherapy was obtained (risk of death reduction by 29%) while the percentage of patients remaining in follow-up was 18%. Analysis of patients with good performance status treated in clinical practice confirms the results from the registration study and emphasizes the importance of taking into consideration clinical factors while qualifying patients for treatment.